Pfizer Suffers Setback In Lipitor Patent Re-Exam
The U.S. Patent and Trademark Office has initially rejected the claims of Pfizer's basic patent for the cholesterol drug Lipitor, which brought in $3.2 billion in sales for the company in...To view the full article, register now.
Already a subscriber? Click here to view full article